Related Experiment Video
Updated: Feb 14, 2026

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
Published on: July 11, 2013
Validating a Selective S1P1 Receptor Modulator Syl930 for Psoriasis Treatment
Ming Ji1,2, Nina Xue1, Fangfang Lai1
1State Key Laboratory of Bioactive Substances and Functions of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College.
A new drug, Syl930, targeting sphingosine-1-phosphate (S1P) signaling, shows significant anti-proliferative and anti-inflammatory effects in animal models of psoriasis. This indicates Syl930
Area of Science:
- Dermatology
- Immunology
- Pharmacology
Background:
- Psoriasis is a chronic inflammatory skin condition.
- T-cell infiltration is a key factor, but mechanisms remain unclear.
- Sphingosine-1-phosphate (S1P) signaling regulates immune cell trafficking and is a potential therapeutic target.
Purpose of the Study:
- To evaluate a novel selective S1P1 modulator, Syl930, for psoriasis treatment.
- To assess Syl930's efficacy in various psoriasis animal models.
Main Methods:
- Oral administration of Syl930.
- Testing in four distinct psoriasis animal models, including sodium lauryl sulfate (SLS)-induced and propranolol-induced models.
- Assessment of skin thickening, cell proliferation, and epidermal/granular layer changes.
Main Results:
- Syl930 demonstrated potent anti-proliferative and anti-inflammatory effects.
- Reduced skin thickening, inhibited basal cell proliferation, and improved granular layer scales.
- Ameliorated key psoriasis hallmarks like parakeratosis and acanthosis in a guinea pig model.
Conclusions:
- Syl930 effectively reduces psoriasis-like pathology in preclinical models.
- The selective S1P1 modulator shows promise as a therapeutic agent for psoriasis.
- Further clinical investigation of Syl930 for psoriasis treatment is warranted.
Related Concept Videos
Reliability and Validity
Internal Receptors
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Data Validation
Key parameters for method validation include:
Data Validation
Nursing assessment guides are generally based on holistic models rather than medical...

